Humanigen

Humanigen FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Humanigen (HGENQ) as of Oct 5, 2026 is 108.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.77 % — a change of 39.43% (higher).

FCF Conversion

108.44 %

YoY

39.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Humanigen is 2026 108.44 % . FCF Conversion Rate (FCF/EBITDA) of Humanigen was 2025 77.77 % . It decreases by 39.43% higher compared to the previous year.

The Humanigen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
82.53 USD
Jan 1, 2016
77.57 USD
Jan 1, 2017
64.80 USD
Jan 1, 2018
51.75 USD
Jan 1, 2019
38.87 USD
Jan 1, 2020
78.03 USD
Jan 1, 2021
77.77 USD
Jan 1, 2022
108.44 USD
The Humanigen FCF Conversion history
YEARFCF ConversionYoY
108.44 %+39.43%
77.77 %-0.33%
78.03 %+100.74%
38.87 %-24.88%
51.75 %-20.14%
64.80 %-16.46%
77.57 %-6.01%
82.53 %-13.82%
95.76 %—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

FCF Conversion Rate (FCF/EBITDA) of Humanigen is 108.44 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Humanigen changed from 77.77 % to 108.44 %, representing a 39.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Humanigen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Humanigen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Humanigen

All Key Metrics — Humanigen